How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?

Anti-CTLA-4 antibodies can induce lasting protection for some melanoma patients. However, their therapeutic potential is limited by significant immunotherapy-related adverse effects (irAE). Here, we argue that the therapeutic effect may be based on an agonist activity that is fundamentally distinct,...

Full description

Saved in:
Bibliographic Details
Published in:Trends in immunology 2018-12, Vol.39 (12), p.953-956
Main Authors: Liu, Yang, Zheng, Pan
Format: Article
Language:English
Subjects:
Animals
Antibodies
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - therapeutic use
Cancer
CTLA-4 Antigen - antagonists & inhibitors
CTLA-4 Antigen - immunology
CTLA-4 protein
Humans
Hypotheses
Immunity
Immunoglobulins
Immunotherapy
Lymphocytes
Melanoma
Neoplasms - drug therapy
Neoplasms - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anti-CTLA-4 antibodies can induce lasting protection for some melanoma patients. However, their therapeutic potential is limited by significant immunotherapy-related adverse effects (irAE). Here, we argue that the therapeutic effect may be based on an agonist activity that is fundamentally distinct, and can be therapeutically differentiated, from the antagonist activity responsible for irAE.
ISSN:1471-4906
1471-4981
DOI:10.1016/j.it.2018.10.009